Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Psyence Group Inc. (C:PSYG)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for PSYG within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 13, 2021 07:30 ET
Psyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker “PSYGF”
Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that, effective today, its common...
Read full article
Oct 12, 2021 10:37 ET
Psyence Group Jamaica Chief Medical Officer Dr. Dingle Spence to Headline Two Conferences on Psychedelics
Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Dr. Dingle Spence, the Chief Medical Officer...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
28.29
12.91
Price to Book - most recent quarter
3.66
3.49
3.21
Price to Cash Flow per share - TTM
--
12.70
13.45
Price to Free Cash Flow per share - TTM
--
20.73
32.88
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Oct 15, 202112,6129,121
Sep 30, 20213,491-37,275
Sep 15, 202140,7669,423
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Psyence Group Inc is a Canada-based company, which provides global psychedelic platform. The Company builds and operates commercial psilocybin cultivation and production facilities. It offers natural psilocybin for the long-term treatment of psychological trauma and its mental health consequences. The Company's natural psychedelics are cultivated in Lesotho. It focuses on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin. It operates across Toronto, Canada; Washington District of Columbia (DC), United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.

See business summary

 

Twitter

Search (past week) for $PSYG.CA

  • No tweets found